These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16206101)

  • 1. Glucose homeostasis abnormalities associated with use of gatifloxacin.
    Frothingham R
    Clin Infect Dis; 2005 Nov; 41(9):1269-76. PubMed ID: 16206101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone.
    Mohr JF; McKinnon PS; Peymann PJ; Kenton I; Septimus E; Okhuysen PC
    Pharmacotherapy; 2005 Oct; 25(10):1303-9. PubMed ID: 16185173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
    Frothingham R
    Pharmacotherapy; 2001 Dec; 21(12):1468-72. PubMed ID: 11765299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
    Iannini PB
    Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan.
    Chou HW; Wang JL; Chang CH; Lee JJ; Shau WY; Lai MS
    Clin Infect Dis; 2013 Oct; 57(7):971-80. PubMed ID: 23948133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients.
    Lodise T; Graves J; Miller C; Mohr JF; Lomaestro B; Smith RP
    Pharmacotherapy; 2007 Nov; 27(11):1498-505. PubMed ID: 17963459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.
    Gavin JR; Kubin R; Choudhri S; Kubitza D; Himmel H; Gross R; Meyer JM
    Drug Saf; 2004; 27(9):671-86. PubMed ID: 15230648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe dysglycemia with the fluoroquinolones: a class effect?
    Aspinall SL; Good CB; Jiang R; McCarren M; Dong D; Cunningham FE
    Clin Infect Dis; 2009 Aug; 49(3):402-8. PubMed ID: 19545207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.
    Graumlich JF; Habis S; Avelino RR; Salverson SM; Gaddamanugu M; Jamma K; Aldag JC
    Pharmacotherapy; 2005 Oct; 25(10):1296-302. PubMed ID: 16185172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient gatifloxacin therapy and dysglycemia in older adults.
    Park-Wyllie LY; Juurlink DN; Kopp A; Shah BR; Stukel TA; Stumpo C; Dresser L; Low DE; Mamdani MM
    N Engl J Med; 2006 Mar; 354(13):1352-61. PubMed ID: 16510739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty.
    Fukuda M; Yamada M; Kinoshita S; Inatomi T; Ohashi Y; Uno T; Shimazaki J; Satake Y; Maeda N; Hori Y; Nishida K; Kubota A; Nakazawa T; Shimomura Y
    Adv Ther; 2012 Apr; 29(4):339-49. PubMed ID: 22529026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
    Scoper SV
    Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting.
    LaPlante KL; Mersfelder TL; Ward KE; Quilliam BJ
    Pharmacotherapy; 2008 Jan; 28(1):82-9. PubMed ID: 18154478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
    Peloquin CA; Hadad DJ; Molino LP; Palaci M; Boom WH; Dietze R; Johnson JL
    Antimicrob Agents Chemother; 2008 Mar; 52(3):852-7. PubMed ID: 18070980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
    Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
    Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moxifloxacin-induced hypoglycemia in a non-diabetic patient.
    Mandavia DR; Virpariya MM; Patel TK; Tripathi CB
    Curr Drug Saf; 2012 Apr; 7(2):183-5. PubMed ID: 22873504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
    Johnson JL; Hadad DJ; Boom WH; Daley CL; Peloquin CA; Eisenach KD; Jankus DD; Debanne SM; Charlebois ED; Maciel E; Palaci M; Dietze R
    Int J Tuberc Lung Dis; 2006 Jun; 10(6):605-12. PubMed ID: 16776446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose homeostasis abnormalities and gatifloxacin.
    Tailor SA; Simor AE; Cornish W; Phillips EJ; Knowles S; Rachlis A
    Clin Infect Dis; 2006 Mar; 42(6):895. PubMed ID: 16477578
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk factors for hyperglycemia in hospitalized adults receiving gatifloxacin: a retrospective, nested case-controlled analysis.
    Mohr JF; Peymann PJ; Troxell E; Lodise TP; Ostrosky-Zeichner L
    Clin Ther; 2008 Jan; 30(1):152-7. PubMed ID: 18343251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions.
    Jones SC; Budnitz DS; Sorbello A; Mehta H
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1099-106. PubMed ID: 23963962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.